A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

HER2-expressing Cancers Clinical Trial

Official title: A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer

Status Active, not recruiting

Clinical Trial Summary

This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced [inoperable] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.

Clinical Trial Description

Part 1 of the study will first evaluate the safety and tolerability and establish the recommended doses (RDs) of zanidatamab in combination with evorpacept (ALX148). Part 2 of the study will evaluate the anti-tumor activity of the combination of zanidatamab plus evorpacept (ALX148) at the RD levels in indication-specific expansion cohorts. ;

Related Conditions & MeSH terms

• HER2-expressing Cancers

• NCT number: NCT05027139
• Study type: Interventional
• Source: Jazz Pharmaceuticals
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: September 15, 2021
• Completion date: April 30, 2025